Schizophrenia is a disease that afflicts 3 million Americans.1
The World Health Organization ranks it as the third most disabling disease in the world.2
To make matters worse, schizophrenia is often misunderstood and the current drugs used to treat it are laden with harmful side effects.
Listen as Eventide CIO Finny Kuruvilla, MD, PhD, explains the symptoms associated with Schizophrenia and the exciting new therapies on the horizon that promise significant quality-of-life improvements for many patients.
1Desai, P.R., K.A. Lawson, J.C. Barner, and K.L. Rascati. “Estimating the Direct and Indirect Costs for Community-Dwelling Patients with Schizophrenia.” Journal of Pharmaceutical Health Services Research 4, no. 4 (Jul 2013): 187-94. Accessed May 27, 2020. http://online library.wiley.com/doi/10.1111/jphs.12027/epdf.
This communication is provided for informational purposes only and expresses views of Eventide Asset Management, LLC ("Eventide"), an investment adviser. There is no guarantee that any investment strategy will achieve its objectives, generate profits, or avoid losses. Eventide's values-based approach to investing may not produce desired results and could result in underperformance compared with other investments. Any reference to Eventide’s Business 360 approach is provided for illustrative purposes only and indicates a general framework of guiding principles that inform Eventide’s overall research process. Investing involves risk including the possible loss of principal. Past performance does not guarantee future results.
Before investing or sending money, an investor should carefully review investment objectives, risks, charges and expenses as provided in prospectuses and other information available at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Eventide Asset Management, LLC serves as investment adviser to the Eventide mutual funds distributed through Northern Lights Distributors, LLC (“NLD”), member FINRA/SIPC. NLD and Eventide are not affiliated entities.